Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of 4P-004 Versus Placebo Injected in the Target Knee Joint of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index (KL 2-4)

Next Previous
X
Search
Trial Profile

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of 4P-004 Versus Placebo Injected in the Target Knee Joint of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index (KL 2-4)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man
  • Acronyms LASARE
  • Sponsors 4Moving Biotech

    • Most Recent Events

    • 10 Jun 2024 Results presented in the 4Moving Biotech Media Release.
    • 26 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 19 Oct 2023 According to a 4Moving Biotech media release, Thirty-four patients have been randomized in 3 sites in Belgium, EU. Results are scheduled for Q1 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top